Key points are not available for this paper at this time.
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
Yarchoan et al. (2017) studied this question.